TENX Tenax Therapeutics, Inc.

0.51
-0.002  -0%
Previous Close 0.51
Open 0.50
Price To book 1.02
Market Cap 14.26M
Shares 28,236,000
Volume 176,841
Short Ratio 3.03
Av. Daily Volume 592,498

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission
  2. Tenax CEO resigns, company to review 'strategic alternatives'
  3. Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update
  4. TENX: 2016 Results; Subgroup Analysis Shows CABG Survival Benefit
  5. Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update
  6. Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017
  7. Tenax Therapeutics to Discuss Year-End 2016 Financial Results and Provide Business Update
  8. TENX: Tenax Reports LEVO-CTS Topline Results
  9. Under Armour, Rite Aid Fall into Tuesday’s 52-Week Low Club
  10. Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
  11. Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM Oncology
  12. Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release
  13. Tenax Therapeutics, Inc. Review of Clinical Trials and Financials
  14. Is KemPharm Inc (KMPH) A Good Stock To Buy?
  15. TENX: LEVO-CTS Enrolment Complete; Anticipate January Topline Readout
  16. Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery
  17. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
  18. Investor Calendar Invites You to the Tenax Therapeutics Third Quarter 2016 Business Review and Update on Thursday, November 10, 2016
  19. Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update